Burden of Hospitalization After Liver Transplantation
Burden of Hospitalization After Liver Transplantation
批准号:
8884052
负责人:
PRATIMA SHARMA
金额:
$8.45万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2017-03-31
关键词:
AddressAgeAwardCaringCharacteristicsChronic DiseaseCirrhosisClinicalComorbidityComplexDataDevelopmentDisease ManagementDonor personEnd stage renal failureEpidemiologyFutureGoalsGraft SurvivalHealth Care CostsHealth Services AccessibilityHospitalizationInterventionInvestigationKidneyKidney TransplantationKnowledgeLeadLifeLinkLiver diseasesMeasuresMedicalModelingModificationOperative Surgical ProceduresOrgan TransplantationOutcomePatient CarePatient-Focused OutcomesPatientsPhenotypeQuality of lifeRegistriesResourcesRiskRisk FactorsSample SizeSolidStagingSurvival RateTimeTransplant RecipientsTransplantationUnited States Centers for Medicare and Medicaid ServicesVariantadministrative databasebasecostevidence basefallsgeographic differencehealth disparityhigh riskhospital readmissionimprovedindexingliver transplantationmortalitynovelpoint of carepredictive modelingpublic health relevancestandard of carestemtool
中文摘要
描述(由申请人提供):肝移植(LT)是失代偿期肝硬化患者唯一可用的治疗和护理标准,每位患者每年的费用超过50万美元。大部分的费用是由于LT后住院和出院后护理。尽管手术和医疗护理的临床进展显著提高了接受LT的患者的生存率和生活质量,但LT后住院对LT后结局产生不利影响。然而,严重缺乏关于负担或LT后住院的数据。LT后终末期肾病(ESRD)是实体器官移植受者的主要并发症之一,也是LT后死亡率的最强预测因素之一。终末期肝病模型(MELD)时代(2002年2月28日之后)的LT后ESRD风险较MELD前增加了15%。我们的初步数据显示LT后ESRD和LT后住院之间存在相关性。有一些单中心研究,检查了30和90天的再入院指数LT后,但是,迄今为止,没有研究已经全面量化的LT接受者的住院治疗的总体负担。该提案的总体目标是全面评估LT后住院治疗的负担。中心假设是患者、捐赠者、移植和中心层面因素的相互作用导致了LT后住院。这些因素不同的基础上从指数LT的时间。本研究的基本原理是了解各种因素之间的关系,有助于LT后住院。这将是一个非常重要的步骤,以揭示LT后住院治疗的机制,可能导致基于证据的护理点干预措施的发展。从该建议的结果中获得的预测模型将作为识别高风险表型的临床工具。修改风险因素
以及开发和实施多管齐下的干预措施,如针对高危表型的慢性病管理策略,可以降低住院率,从而改善患者护理,从而提高生存率,改善生活质量,降低资源利用率。目标1:根据受者、供者、移植者以及中心水平的特征,量化年龄校正率并确定LT后早期和晚期住院的风险因素。目的2:根据受者因素建立并验证LT后早期和晚期住院的预测模型。
英文摘要
DESCRIPTION (provided by applicant): Liver transplantation (LT) is the only available treatment and standard of care for patients with decompensated cirrhosis with a per-patient cost of over half a million dollars per year. Majority of this cost is due to the post-LT hospitalizatio and post-discharge care. Although clinical advances in surgical and medical care have significantly improved survival rates and quality of life of patients undergoing LT, post-LT hospitalizations impact post-LT outcomes adversely. However, data are severely lacking with respect to the burden or post-LT hospitalization. Post- LT end stage renal disease (ESRD) is one of the major co-morbidities among solid organ transplant recipients and is among the strongest predictors of post-LT mortality. The risk of post- LT ESRD has increased by 15% in the Model for End stage liver disease (MELD) era (after 2/28/2002) compared to pre-MELD era. Our preliminary data showed an association between post-LT ESRD and post-LT hospitalizations. There are a few single-center studies that examined the 30- and 90-day readmission after index LT. However, there are no studies to date that have comprehensively quantified the overall burden of hospitalizations among LT recipients. The overarching goal of this proposal is to comprehensively evaluate the burden of post-LT hospitalizations. The central hypothesis is that the interplay of patient-, donor-, transplant-, and center-level factors contribte to post-LT hospitalization. These factors differ based upon the timing from the index LT. The rationale for this study is to understand the relationship between various factors that contribute to post-LT hospitalization. This would be an extremely important step towards unfolding the mechanism behind post-LT hospitalization that may lead to evidence-based development of point of care interventions. The predictive models obtained from the results of this proposal would serve as clinical tools in identifying the high risk phenotypes. Modification of risk factors
as well as development and implementation of multi- pronged interventions such as chronic disease management strategies directed toward high risk phenotype may reduce the hospitalization rates, and thus lead to improved patient care and hence, increased survival, improved quality of life, and decreased resource utilization. Aim 1: To quantify the age-adjusted rates and identify the risk factors of early and late post-LT hospitalization based upon the recipient-, donor-, transplant- as well as center-level characteristics. Aim 2: To develop and validate the predictive model for early and late post-LT hospitalization based upon recipient factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predicting the burden of renal disease among liver transplant recipients
-
批准号:8099229
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2011
-
负责人:PRATIMA SHARMA
-
依托单位:
Predicting the burden of renal disease among liver transplant recipients
-
批准号:8661169
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2011
-
负责人:PRATIMA SHARMA
-
依托单位:
Predicting the burden of renal disease among liver transplant recipients
-
批准号:8848809
-
项目类别:
-
资助金额:$15.34万
-
财政年份:2011
-
负责人:PRATIMA SHARMA
-
依托单位:
Predicting the burden of renal disease among liver transplant recipients
-
批准号:8463163
-
项目类别:
-
资助金额:$15.3万
-
财政年份:2011
-
负责人:PRATIMA SHARMA
-
依托单位:
Predicting the burden of renal disease among liver transplant recipients
-
批准号:8235073
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2011
-
负责人:PRATIMA SHARMA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: